Focus Partners Advisor Solutions LLC Acquires Shares of 3,182 Medpace Holdings, Inc. $MEDP

Key Points

• Focus Partners Advisor Solutions acquired 3,182 Medpace shares worth approximately $1.685 million, while institutional investors collectively own 77.98% of the company.
• Medpace reported stronger-than-expected quarterly results, with EPS of $4.25 and revenue of $707.33 million, representing 17.2% year-over-year growth. The company guided for fiscal 2026 EPS of $17.25–$17.95.
• Analysts maintain a consensus “Hold” rating with an average price target of $584.18; meanwhile, Medpace’s CEO recently sold 17,610 shares for about $10.7 million.

Focus Partners Advisor Solutions LLC acquired a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 3,182 shares of the company's stock, valued at approximately $1,685,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. AQR Capital Management LLC grew its position in Medpace by 31.6% in the 4th quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company's stock valued at $758,061,000 after buying an additional 324,293 shares during the last quarter. Wasatch Advisors LP raised its position in Medpace by 14.0% during the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company's stock worth $296,853,000 after buying an additional 116,354 shares during the last quarter. Geode Capital Management LLC raised its position in Medpace by 3.8% during the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company's stock worth $374,836,000 after buying an additional 24,625 shares during the last quarter. Invesco Ltd. raised its position in Medpace by 18.9% during the 3rd quarter. Invesco Ltd. now owns 537,407 shares of the company's stock worth $276,313,000 after buying an additional 85,517 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in shares of Medpace by 8.3% in the 1st quarter. Renaissance Technologies LLC now owns 504,668 shares of the company's stock worth $242,337,000 after acquiring an additional 38,760 shares during the period. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Stock Down 0.6%

NASDAQ:MEDP opened at $578.50 on Friday. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90. The stock has a market cap of $16.15 billion, a PE ratio of 33.91, a price-to-earnings-growth ratio of 2.58 and a beta of 1.15. The firm's fifty day simple moving average is $536.23 and its 200-day simple moving average is $492.35.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm had revenue of $707.33 million during the quarter, compared to analysts' expectations of $689.51 million. During the same quarter last year, the business earned $3.10 earnings per share. The business's revenue for the quarter was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities analysts anticipate that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on MEDP. Jefferies Financial Group downgraded shares of Medpace from a "buy" rating to a "hold" rating and lifted their target price for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. Truist Financial raised their price objective on shares of Medpace from $462.00 to $609.00 and gave the company a "hold" rating in a research report on Friday, July 24th. Barclays set a $600.00 price objective on Medpace in a report on Thursday, July 23rd. Weiss Ratings upgraded Medpace from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday. Finally, Leerink Partners set a $620.00 target price on Medpace in a research note on Thursday, July 23rd. Three investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat.com, Medpace currently has an average rating of "Hold" and a consensus target price of $584.18.

Insider Activity at Medpace

In other Medpace news, CEO August J. Troendle sold 17,610 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $605.11, for a total value of $10,655,987.10. Following the completion of the transaction, the chief executive officer directly owned 615,802 shares of the company's stock, valued at approximately $372,627,948.22. This trade represents a 2.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the sale, the general counsel owned 20,343 shares of the company's stock, valued at approximately $9,154,350. The trade was a 44.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 67,195 shares of company stock valued at $37,989,998. 20.50% of the stock is currently owned by corporate insiders.

Medpace Profile

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source